296 related articles for article (PubMed ID: 30593782)
21. Effects of intranasal and peripheral oxytocin or gastrin-releasing peptide administration on social interaction and corticosterone levels in rats.
Kent P; Awadia A; Zhao L; Ensan D; Silva D; Cayer C; James JS; Anisman H; Merali Z
Psychoneuroendocrinology; 2016 Feb; 64():123-30. PubMed ID: 26658172
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and pharmacodynamics of intranasally administered selegiline nanoparticles with improved brain delivery in Parkinson's disease.
Sridhar V; Gaud R; Bajaj A; Wairkar S
Nanomedicine; 2018 Nov; 14(8):2609-2618. PubMed ID: 30171904
[TBL] [Abstract][Full Text] [Related]
23. Brain pharmacokinetics of neurotoxin-loaded PLA nanoparticles modified with chitosan after intranasal administration in awake rats.
Zhang X; Liu L; Chai G; Zhang X; Li F
Drug Dev Ind Pharm; 2013 Nov; 39(11):1618-24. PubMed ID: 24087853
[TBL] [Abstract][Full Text] [Related]
24. Targeting of the kynurenic acid across the blood-brain barrier by core-shell nanoparticles.
Varga N; Csapó E; Majláth Z; Ilisz I; Krizbai IA; Wilhelm I; Knapp L; Toldi J; Vécsei L; Dékány I
Eur J Pharm Sci; 2016 Apr; 86():67-74. PubMed ID: 26924227
[TBL] [Abstract][Full Text] [Related]
25. Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders.
Islam SU; Shehzad A; Ahmed MB; Lee YS
Molecules; 2020 Apr; 25(8):. PubMed ID: 32326318
[TBL] [Abstract][Full Text] [Related]
26. Nano carriers for drug transport across the blood-brain barrier.
Li X; Tsibouklis J; Weng T; Zhang B; Yin G; Feng G; Cui Y; Savina IN; Mikhalovska LI; Sandeman SR; Howel CA; Mikhalovsky SV
J Drug Target; 2017 Jan; 25(1):17-28. PubMed ID: 27126681
[TBL] [Abstract][Full Text] [Related]
27. Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route.
Patel S; Chavhan S; Soni H; Babbar AK; Mathur R; Mishra AK; Sawant K
J Drug Target; 2011 Jul; 19(6):468-74. PubMed ID: 20958095
[TBL] [Abstract][Full Text] [Related]
28. Cerebral and extracerebral distribution of radioactivity associated with oxytocin in rabbits after intranasal administration: Comparison of TTA-121, a newly developed oxytocin formulation, with Syntocinon.
Ishii D; Kageyama M; Umeda S
PLoS One; 2021; 16(12):e0261451. PubMed ID: 34929003
[TBL] [Abstract][Full Text] [Related]
29. Haloperidol-loaded intranasally administered lectin functionalized poly(ethylene glycol)-block-poly(D,L)-lactic-co-glycolic acid (PEG-PLGA) nanoparticles for the treatment of schizophrenia.
Piazza J; Hoare T; Molinaro L; Terpstra K; Bhandari J; Selvaganapathy PR; Gupta B; Mishra RK
Eur J Pharm Biopharm; 2014 May; 87(1):30-9. PubMed ID: 24560967
[TBL] [Abstract][Full Text] [Related]
30. Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting.
Jafarieh O; Md S; Ali M; Baboota S; Sahni JK; Kumari B; Bhatnagar A; Ali J
Drug Dev Ind Pharm; 2015; 41(10):1674-81. PubMed ID: 25496439
[TBL] [Abstract][Full Text] [Related]
31. Advances in the field of intranasal oxytocin research: lessons learned and future directions for clinical research.
Quintana DS; Lischke A; Grace S; Scheele D; Ma Y; Becker B
Mol Psychiatry; 2021 Jan; 26(1):80-91. PubMed ID: 32807845
[TBL] [Abstract][Full Text] [Related]
32. Labeled oxytocin administered via the intranasal route reaches the brain in rhesus macaques.
Lee MR; Shnitko TA; Blue SW; Kaucher AV; Winchell AJ; Erikson DW; Grant KA; Leggio L
Nat Commun; 2020 Jun; 11(1):2783. PubMed ID: 32494001
[TBL] [Abstract][Full Text] [Related]
33. Editorial of Special Issue "Surface-Functionalized Nanoparticles as Drug Carriers".
Layek B; Singh J
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31861113
[TBL] [Abstract][Full Text] [Related]
34. Mathematical Modeling and Simulation to Investigate the CNS Transport Characteristics of Nanoemulsion-Based Drug Delivery Following Intranasal Administration.
Kadakia E; Bottino D; Amiji M
Pharm Res; 2019 Mar; 36(5):75. PubMed ID: 30923914
[TBL] [Abstract][Full Text] [Related]
35. Intranasal Oxytocin: Myths and Delusions.
Leng G; Ludwig M
Biol Psychiatry; 2016 Feb; 79(3):243-50. PubMed ID: 26049207
[TBL] [Abstract][Full Text] [Related]
36. Oxytocin by intranasal and intravenous routes reaches the cerebrospinal fluid in rhesus macaques: determination using a novel oxytocin assay.
Lee MR; Scheidweiler KB; Diao XX; Akhlaghi F; Cummins A; Huestis MA; Leggio L; Averbeck BB
Mol Psychiatry; 2018 Jan; 23(1):115-122. PubMed ID: 28289281
[TBL] [Abstract][Full Text] [Related]
37. Saliva oxytocin measures do not reflect peripheral plasma concentrations after intranasal oxytocin administration in men.
Quintana DS; Westlye LT; Smerud KT; Mahmoud RA; Andreassen OA; Djupesland PG
Horm Behav; 2018 Jun; 102():85-92. PubMed ID: 29750971
[TBL] [Abstract][Full Text] [Related]
38. Development and evaluation of carboplatin-loaded PCL nanoparticles for intranasal delivery.
Alex AT; Joseph A; Shavi G; Rao JV; Udupa N
Drug Deliv; 2016 Sep; 23(7):2144-2153. PubMed ID: 25544603
[TBL] [Abstract][Full Text] [Related]
39. Acute and repeated intranasal oxytocin administration exerts anti-aggressive and pro-affiliative effects in male rats.
Calcagnoli F; Kreutzmann JC; de Boer SF; Althaus M; Koolhaas JM
Psychoneuroendocrinology; 2015 Jan; 51():112-21. PubMed ID: 25305547
[TBL] [Abstract][Full Text] [Related]
40. "Application of Box-Behnken design for optimization and development of quetiapine fumarate loaded chitosan nanoparticles for brain delivery via intranasal route* ".
Shah B; Khunt D; Misra M; Padh H
Int J Biol Macromol; 2016 Aug; 89():206-18. PubMed ID: 27130654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
